Skip to Content

Dyne Therapeutics Inc Ordinary Shares DYN

Morningstar Rating
$25.85 −1.53 (5.59%)
View Full Chart
Unlock our analysis with Morningstar Investor

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

DYN is trading at a 42% discount.
Price
$25.88
Fair Value
$14.48
Uncertainty
Extreme
1-Star Price
$918.74
5-Star Price
$5.53
Economic Moat
Lkr
Capital Allocation
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if DYN is a good fit for your portfolio.

News

Trading Information

Previous Close Price
$27.38
Day Range
$25.5427.52
52-Week Range
$6.4030.27
Bid/Ask
$25.00 / $27.60
Market Cap
$2.23 Bil
Volume/Avg
652,554 / 1.4 Mil

Key Statistics

Price/Earnings (Normalized)
Price/Sales
Dividend Yield (Trailing)
Dividend Yield (Forward)
Total Yield

Company Profile

Dyne Therapeutics Inc is a biotechnology company focused on providing therapeutics for patients with genetically driven diseases. The company overcomes the limitations of muscle tissue delivery and modern oligonucleotide therapeutics for muscle diseases. The company is developing therapies for muscle disorders like Myotonic dystrophy, Duchenne muscular dystrophy, and Facioscapulohumeral muscular dystrophy.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
141

Comparables

Valuation

Metric
DYN
CBAY
PLRX
Price/Earnings (Normalized)
Price/Book Value
18.0812.651.79
Price/Sales
111.01525.49
Price/Cash Flow
Price/Earnings
DYN
CBAY
PLRX

Financial Strength

Metric
DYN
CBAY
PLRX
Quick Ratio
2.4110.7017.43
Current Ratio
2.5310.9617.72
Interest Coverage
−5.27−145.34
Quick Ratio
DYN
CBAY
PLRX

Profitability

Metric
DYN
CBAY
PLRX
Return on Assets (Normalized)
−88.69%−30.06%−22.68%
Return on Equity (Normalized)
−114.25%−51.97%−24.50%
Return on Invested Capital (Normalized)
−102.56%−30.87%−28.46%
Return on Assets
DYN
CBAY
PLRX
See how this stock stacks up to its competitors with Morningstar Investor

Biotechnology Industry Comparables

Ticker
Name
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
NVO
Novo Nordisk A/S ADRSbsrwgwpyjNpzwy$564.6 Bil
REGN
Regeneron Pharmaceuticals IncCvjtcqvlWvdmrkn$102.8 Bil
VRTX
Vertex Pharmaceuticals IncRjsrslkfSgpttm$102.5 Bil
MRNA
Moderna IncXrrbwlsDjz$41.0 Bil
ARGX
argenx SE ADRHwrtzbfsqHxny$22.8 Bil
BNTX
BioNTech SE ADRDtqnbvfFfk$21.7 Bil
ALNY
Alnylam Pharmaceuticals IncNwwcgpfpvXhskht$18.8 Bil
BMRN
Biomarin Pharmaceutical IncHtsdhnsjjVwmwsr$17.4 Bil
RPRX
Royalty Pharma PLC Class AQzpwysryPbwpr$12.6 Bil
INCY
Incyte CorpVtspxkybbHndbtfp$12.1 Bil

Sponsor Center